Healthcare and pharma tax expertise. LC 214/2025 specific regime.

Healthcare tax landscape — three sub-sectors

Brazilian healthcare taxation operates across three distinct regulatory regimes:

• Health insurance operators (planos de saúde) — ANS-regulated entities subject to specific PIS/COFINS rules and ICMS exclusions. Recovery opportunities on Tema 69 STF and contractual provisions;
• Hospitals and clinics — service providers under ISS, with potential constitutional immunity for non-profit entities (Article 150, VI, "c" of the Federal Constitution);
• Pharmaceutical industry and labs — manufacturers subject to monophasic PIS/COFINS regime (Law 10.147/2000) — taxes collected at industrial level, exempt at distributor/retailer level. Substantial recovery opportunities when classification was incorrect.

Health-plan operators currently assess PIS/COFINS cumulatively at a combined 4.65% on premiums, with no credit. The base deductions are anchored in article 3, §9 of Law 9.718/1998 (added by MP 2.158-35/2001): ceded co-responsibility, the portion allocated to technical provisions, and indemnities for claims actually paid. There is, however, no binding STJ repetitive appeal or Theme that has definitively fixed the exact perimeter of this base of calculation — each exclusion needs its own technical support. The SUS reimbursement (article 32 of Law 9.656/1998) is a related matter and was declared constitutional by the Federal Supreme Court (Theme 345, RE 597.064/RJ, Justice Gilmar Mendes, judged 07/02/2018), with adversarial process and full defense assured at the administrative level. Medical cooperatives (Unimed) lost the blanket PIS/COFINS exemption — the Supreme Court, in Theme 177 (RE 598.085/RJ, Justice Luiz Fux, 06/11/2014), upheld the repeal of the LC 70/1991 exemption; the "typical cooperative act" thesis (Themes 323 and 536) remains in discussion and cannot be treated as settled.

Under the Reform, operators move to a specific regime (articles 234 to 243 of LC 214/2025), with their own base of calculation (article 235) and a 60% reduction (article 237); pet/veterinary health plans carry a 30% reduction (article 243). The base excludes medical-audit claim denials (glosa) and financial income not tied to premiums.

The Brazilian health sector reaches roughly 10% of GDP, underscoring why these regimes carry such fiscal weight.

For the broader Brazilian Tax Reform context, see Brazilian Tax Reform 2026—2033.

LC 214/2025 — Specific regime for health services

The Brazilian Tax Reform Complementary Law 214/2025 establishes specific reduced-rate regimes for sectors of public interest. Health services qualify for a 60% reduction in CBS/IBS, health-plan operators fall under a dedicated regime (Articles 234—243), and medicines listed in Annex XIV are taxed at the zero rate.

Reduced rate for health services

Health services qualify for a 60% reduction in IBS/CBS rates: the chapter rule is article 128, with the reduction set by article 130 and Annex III (NBS classification — consultations, hospital stays, exams, physiotherapy, dentistry). Medical devices follow the same 60% reduction under article 131 and Annex IV. The reductions apply to the reference rate, which has not yet been fixed — the 26.5% figure is only a trigger ceiling (article 475, §11), not the rate — so any post-reduction effective load is an illustrative projection.

The map of the health regime under the Reform pulls together, category by category, the reduction that applies and the exact legal basis: health services at −60% (arts. 128 & 130 + Annex III), medical devices at −60% (art. 131 + Annex IV), accessibility items for people with disabilities at −60% (art. 132 + Annex V), listed medicines at the zero rate (art. 146 + Annex XIV), other Anvisa-registered medicines at −60% under the general rule (art. 133) and health-plan operators at −60% on their own base (arts. 234 to 243). The IPI, in turn, is reduced to zero / NT — and not extinguished —, kept on a residual basis for the Manaus Free Trade Zone.

Zero-rate pharmaceuticals (Annex XIV)

For medicines there are two tiers. Those listed in Annex XIV (vaccines, oncology, antiretrovirals, immunological products and other essential categories) are taxed at the zero rate under article 146; all other Anvisa-registered medicines fall under the general rule of a 60% reduction (article 133) — there is no separate annex for the 60% medicines, and Annex XIV is exclusively the zero-rate list. The same product can carry a different rate depending on who buys it — zero for public bodies and immune CEBAS entities, a 60% reduction for private hospitals, clinics and pharmacies — so the supplier must validate the buyer's status before applying the relief.

Implementation

• Phased 2027—2032 alongside general IBS/CBS implementation;
• Qualification criteria require formal recognition by competent regulator (ANVISA, ANS, CFM/CRMs);
• Pricing strategy — operators should model net impact on patient pricing and insurance contracts;
• Compliance complexity — service classification becomes critical (which services qualify for reduced rate vs standard).

Monofásico PIS/COFINS — pharmaceutical recovery

Pharmaceutical products operate under the monophasic regime (Law 10.147/2000). Its article 1 concentrates taxation at the manufacturer/importer (PIS 2.1% + COFINS 9.9% = 12% combined); article 2 zero-rates resale by distributors and pharmacies; and article 3 creates the presumed credit that gives rise to the "positive list". Within this regime, the STJ settled in Theme 1.093 (REsp 1.894.741/RS, 1st Section, judged 27/04/2022) that no credit may be taken on the acquisition cost of the goods — the reseller does not credit. The thesis here is therefore not credit recovery on resale, but correct classification and use of the manufacturer's legitimate credits (article 3, presumed credit).

The most technically sensitive point is the mechanics of the presumed credit under article 3 of Law 10.147/2000. For the medicines on the positive list — TIPI headings 30.03 and 30.04 —, the manufacturer/importer that joins the CMED system (a conduct-adjustment commitment with the Medicine Market Regulation Chamber, under Decree 3.803/2001) computes a presumed credit that, in practice, neutralises the monophasic burden on those products: the PIS/COFINS debit (2.1% + 9.9%) is offset by the equivalent presumed credit, zeroing the effective load on the listed items. It is not an automatic relief — it depends on formal adherence to CMED and on correct classification of the product on the positive list; a medicine outside the list remains taxed at the full monophasic burden.

Common recovery opportunities

• Classification errors — wholesalers and retailers paying PIS/COFINS on monofásico products (should be zero) can recover 5 years retrospective;
• Returns and discounts — proper deduction of returns from monofásico tax base, often overlooked;
• Tema 69 STF — ICMS exclusion from monofásico PIS/COFINS base, applicable to manufacturers;
• Reimbursement mechanics — when retailer sells below presumed margin used for ICMS-ST, refund applies (Theme 201 STF).

Typical pharmaceutical wholesaler (BRL 500M revenue) operating with classification errors recovers BRL 10—50M over 5-year retrospective window.

Hospital-equivalence: the reduced IRPJ (8%) and CSLL (12%) base in the Presumed Profit regime

In the Presumed Profit regime (Lucro Presumido), the law presumes a percentage of profit on revenue. For services in general, that presumed base is 32% (Law 9.249/1995, article 15, §1, III, "a"). For hospital services and diagnostic-aid and therapy services, however, the base returns to the ordinary levels: 8% for IRPJ (article 15, caput) and 12% for CSLL (article 20, as amended by Law 11.727/2008, in force since 01/01/2009). This is the so-called hospital-equivalence — the same revenue is then taxed on a much smaller presumed base.

Three points delimit the scope of the benefit, with no room for any promise of result:

• It only applies in the Presumed Profit regime. Under Actual Profit (Lucro Real), taxable income comes from the accounts (the actual result), not from a presumed base — which is why the 8%/12% reduction does not have the same practical effect.
• The saving depends on qualifying, not on the mere medical activity. Having physicians on staff is not enough; the legal requirements and the objective concept of hospital service must be met (covered in the next section).
• Retroactive recovery. A taxpayer that wrongly paid on 32% may, as a rule, reclaim the excess of the last 5 years (CTN, article 168, I), plus the Selic rate, on documentary proof of qualification — with no guarantee of result, which depends on the concrete analysis of each financial year.

Who qualifies: the STJ objective concept (Theme 217) and the two statutory requirements

Access to the reduced base was settled by the STJ in a repetitive appeal. In REsp 1.116.399/BA (Theme 217, 1st Section, Justice Benedito Gonçalves, judged 28/10/2009), the Court defined "hospital services" in an objective way: what matters is the nature of the activity — directly aimed at promoting health —, regardless of whether the facility has hospitalisation or beds. Under this thesis, simple medical consultations are left out, since they do not amount to hospital services and diagnostic-aid and therapy services.

On top of that objective criterion, the legislation adds two cumulative requirements (Law 11.727/2008 + IN RFB 1.700/2017, article 33):

1. Being a business company (sociedade empresária) — the provider must be organised as a business company; a simple company (sociedade simples) defeats the benefit.
2. Meeting ANVISA standards — complying with the physical-structure and operating requirements, notably RDC 50/2002 (physical planning of healthcare-assistance establishments).

Article 33 of IN RFB 1.700/2017 operates by the positive route: it lists the activities that qualify as hospital services and diagnostic-aid and therapy services — among them physiotherapy, speech therapy, clinical pathology, imaging and radiology, pathological anatomy and cytopathology, nuclear medicine, clinical analyses, endoscopy, radiotherapy, chemotherapy, dialysis and hyperbaric oxygen therapy. The exclusion of simple consultations, it should be noted, is not the wording of article 33: it flows from the objective thesis settled in Theme 217, which distinguishes the hospital service from the mere consultation. Qualification therefore requires reading the rule (positive list + business company + ANVISA) and the case law together.

ISS on health services: fixed ISS for single-profession firms and the 2025 STJ milestone

The general rule for ISS on health services is taxation on the price of the service, at a rate ranging from 2% (the floor of LC 157/2016, article 8-A) to 5% (the ceiling of LC 116/2003, article 8, II), depending on the municipality. The services sit in item 4 of the list annexed to LC 116/2003 — 4.01 (medicine and biomedicine), 4.02 (clinical analyses, imaging, radiotherapy, chemotherapy, MRI) and 4.03 (hospitals, clinics, laboratories).

There is, however, a relevant exception: the fixed ISS per qualified professional of the so-called single-profession firms, provided for in article 9, §§1 and 3, of DL 406/1968. This regime survives: STF Precedent 663 confirmed its reception by the 1988 Constitution, and LC 116/2003 (article 10) repealed only articles 8, 10, 11 and 12 of DL 406 — expressly preserving article 9. Under this regime, ISS is computed as a fixed amount per qualified professional, not on turnover.

The 2025 milestone is in Theme 1.323 of the STJ (REsp 2.162.486/SP, 1st Section, Justice Afrânio Vilela, judged 08/10/2025): the Court held that adopting the limited-liability form does not, by itself, bar the fixed ISS, provided three cumulative requirements are met — (i) the services are rendered personally by the partners themselves; (ii) individual technical responsibility; and (iii) the absence of a business structure that removes the personal character. Conversely, the benefit is defeated by production factors prevailing over personal activity, the pursuit of more than one connected activity, and the outsourcing of services. There is therefore no automatic fixed ISS for every limited-liability firm of physicians: a business character defeats the regime, and the analysis is case by case. The ISS amount per professional varies by municipality. The definition of the municipality competent for ISS on health services and the treatment of telemedicine and SaaS are detailed further on, in the section on telemedicine, healthtechs and tax adaptation.

CEBAS-health in depth: the 60%-to-SUS rule, the gratuity route and how immunity is lost

To enjoy the immunity from social-security contributions (CF, article 195, §7), a philanthropic hospital needs CEBAS (Certification of a Charitable Social Assistance Entity). In healthcare, the certification has its own rule: it requires a contract, agreement or similar instrument with the SUS manager and the annual evidence that at least 60% of hospital admissions and outpatient care were allocated to the SUS (LC 187/2021, article 9, I and II).

There is an alternative route through gratuity (LC 187/2021, article 12) for an entity that does not reach the SUS percentage: applying in gratuity, according to the band of SUS actually served, 20%, 10% or 5% of revenue. Renewal of the certificate considers the average of the period (article 11), respecting a minimum of 50% in each year.

It is essential to distinguish the two immunities that protect these entities:

• Immunity from taxes (CF, article 150, VI, "c") — reaches IPTU, ITBI, IRPJ, among others, and has as its requirements those of CTN article 14.
• Immunity from contributions (CF, article 195, §7) — reaches the employer INSS quota, the RAT/SAT, COFINS, CSLL and also PIS, whose inclusion in the scope of the immunity was confirmed by the STF in Theme 432.

As to the loss of immunity: failure to meet the requirements of CTN article 14 authorises the authority to suspend the benefit (CTN, article 14, §1), in line with the certification-cancellation procedure provided for in LC 187/2021. It is worth noting that CEBAS is declaratory, not constitutive, of the right to immunity (STJ, Precedent 612) — the certificate recognises a pre-existing situation of compliance with the requirements. Finally, in ADI 4.480, the STF held that the material conditions of the article 195, §7 immunity can only be required by complementary law — without striking down the entire former regime of Law 12.101/2009, but only the provisions that imposed counterparts by ordinary law; Law 12.101/2009 was later repealed by LC 187/2021.

Innovation and incentives in the pharmaceutical industry: Lei do Bem, incentivised regions and the Reform transition

The pharmaceutical industry is research-intensive, and two groups of incentives on income (IRPJ/CSLL) deserve special attention — precisely because they fall outside the dual VAT and, for that reason, survive the consumption Reform.

Lei do Bem (Law 11.196/2005). For companies under Actual Profit (Lucro Real), research-and-development outlays are already deductible as an expense (article 17) and, in addition, the law authorises an additional exclusion from the IRPJ/CSLL base (article 19):

• 60% of R&D outlays, as the base exclusion;
• 70%, if there is an increase of up to 5% in the number of researchers dedicated to R&D;
• 80%, if the increase in researchers exceeds 5%;
• +20% additional on the outlay relating to a granted patent or registered cultivar (article 19, §§1 to 3).

The benefit requires Actual Profit, the calculation of fiscal profit in the period, tax compliance and the provision of information to the MCTI — leaving out companies under Presumed Profit and the Simples Nacional.

Incentivised regions (SUDENE/SUDAM). Pharmaceutical plants installed within the areas served by SUDENE (Northeast) and SUDAM (Amazon) can obtain a 75% reduction in IRPJ for 10 years (MP 2.199-14/2001, article 1), with a deadline to file the requests until 31/12/2028 (Law 14.753/2023). Add to this the positive-list presumed credit (Law 10.147/2000, article 3, in conjunction with Decree 3.803/2001), which zeroes the monophasic burden for those who follow CMED.

The Reform message. In 2027, PIS/COFINS and the drug monophasic regime are extinguished and replaced by the non-cumulative CBS. That hits the taxation of consumption — not of income. Lei do Bem and the SUDENE/SUDAM incentives fall on IRPJ/CSLL and, for that reason, remain in force after the Reform. For the industry, planning around innovation and industrial location remains a relevant tax lever. See tax planning.

The other side of the counter: pharmacies, drugstores and distributors (Simples, ICMS-ST and the Reform turn)

For pharmacies, drugstores and distributors, the tax game changes in nature — the focus moves away from the industry and onto resale and the correct calculation of the concentrated regimes.

Simples Nacional. An opting pharmacy must segregate, in the PGDAS-D, the resale receipts of medicines subject to the monophasic regime (LC 123/2006, article 18, §4-A, I, in conjunction with §12). On those receipts, the DAS is computed without the PIS/COFINS portion (already collected at the industry), under Resolution CGSN 140/2018 — and the same reasoning applies to receipts subject to ICMS-ST. Failing to segregate means paying twice taxes already collected at the origin; once the failure is identified, a request for review of the last 5 years is available, always on proof of the composition of the receipts — it is not automatic or guaranteed recovery, it depends on correct segregation in the PGDAS-D.

ICMS-ST on medicines. Tax substitution on medicines is governed by ICMS Agreement (Convênio) 234/2017 (in conjunction with Agreement 142/2018), with a base of calculation usually anchored in the PMC/CMED (the regulated maximum consumer price). When the sale to the consumer takes place below the presumed base of the ST, a right to refund of the difference arises, as the STF recognised in Theme 201 (RE 593.849/MG). The effective rate, the MVA and the list of participating states vary by state and by version of the agreement — they require case-by-case checking. On the distribution-incentives side, the so-called fiscal war and its validation follow the regime of LC 160/2017 in conjunction with ICMS Agreement 190/2017.

The Reform turn. With the end of the monophasic regime in 2027, the pharmacy goes back to assessing IBS/CBS with a right to credit on acquisitions — a non-cumulative model, link by link. Medicines in Annex XIV are at the zero rate (article 146), while the others registered with Anvisa carry a 60% reduction under the general rule (article 133, §2, conditioned on TAC/CMED). The transition changes the logic of margin and pricing in pharmaceutical retail and must enter the modelling from now on.

OPME, medical devices and vaccines: the three-layer map (Reform, state ICMS and import)

OPME (orthoses, prostheses and special materials), medical devices and vaccines require reading in three layers that coexist during the transition — confusing them is the main source of classification error.

Layer 1 — Reform (LC 214/2025).

• Medical devices: 60% reduction (article 131 + Annex IV), conditioned on regularisation with Anvisa; the annex is reviewed every 120 days.
• Accessibility for people with disabilities: 60% reduction (article 132 + Annex V).
• Listed medicines and vaccines: zero rate (article 146 + Annex XIV), item by item — a zero-rate treatment (not an "exemption").

Layer 2 — state ICMS (during the transition). These are authorising benefits that depend on internalisation by each state:

• ICMS Agreement 1/99 — equipment, supplies and OPME (prostheses, pacemakers, catheters, implants), extended by Agreement 78/25 until 31/12/2026 (reference to be confirmed);
• ICMS Agreement 162/94 — medicines intended for cancer treatment;
• ICMS Agreement 126/2010 — orthoses, prostheses and accessibility items for people with disabilities.

Agreement 1/99 reaches equipment, supplies and OPME — not the medicines for serious illness, whose cancer treatment runs through Agreement 162/94. Operations with OPME usually also require a special ICMS-ST regime with a dedicated NF-e for the cycle of shipment, return and sale of the material actually applied to the patient.

Layer 3 — import. The entry of equipment and supplies from abroad involves: PIS/COFINS-Import (Law 10.865/2004, article 8 — 1.65% + 7.6%), with statutory authority for a zero rate on health products (article 8, §11, II); the ex-tariff (CAMEX/GECEX) for equipment with no domestic equivalent; and the Drawback-suspension and RECOF regimes. Each item demands verification of the NCM code and of Anvisa regularisation, product by product.

How TaxUp acts in healthcare

• LC 214/2025 qualification analysis — service classification mapping for reduced-rate regime, ANS/ANVISA/CFM compliance verification, customer pricing impact modeling;
• Monofásico recovery — PIS/COFINS classification audit, returns and discounts treatment review, retrospective recovery via PER/DCOMP;
• Constitutional immunity — for non-profit hospitals and Santas Casas there are two distinct immunities: tax-on-income/property immunity (CF article 150, VI, "c" + the requirements of CTN article 14) and social-security contribution immunity (CF article 195, §7), whose material requirements depend on a complementary law — STF Theme 32 (RE 566.622/RS, judged 23/02/2017). The contribution immunity reaches the employer INSS quota, COFINS and CSLL, and also PIS, whose inclusion in the scope was confirmed by the STF in Theme 432. CEBAS certification is now governed by LC 187/2021, and it is declaratory, not constitutive, of the right to immunity (STJ Precedent 612) — the certificate recognises a pre-existing situation of compliance with the requirements. We handle immunity validation and historical recovery where denied;
• ANS-regulated operators — base deductions anchored in article 3, §9 of Law 9.718/1998, healthcare exclusions analysis, and the move to the specific regime (arts. 234—243 LC 214/2025);
• Telemedicine and healthtech ISS — health services sit in item 4 of the LC 116/2003 list (subitems 4.01—4.03); ISS is due at the provider's establishment (article 3 caput + article 4), and STF ADI 5835 (judged 02/06/2023) struck down the attempt to shift health-plan ISS to the taker's municipality. Health SaaS is ISS, not ICMS (STF ADI 1.945 + ADI 5.659, merits judged 18/02/2021, ex nunc effects from early March 2021; custom software follows Theme 590, RE 688.223/PR); Law 14.510/2022 is the regulatory — not tax — framework for telehealth;
• Tax Reform transition — strategic positioning for 2027—2032 phase-in, contract repricing with insurance and corporate clients.

Senior consultant-led engagement with technical depth specific to ANS regulation, ANVISA classification, and healthcare-specific tax precedents.